Author

Xiaokun Shen

Convalife (China)ORCID 0000-0003-3999-5191Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Xiaokun Shen1 paper · Jinzhou Medical University

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1

Frequent Co-Authors

Chengliang Hu· 1 shared Chunhao YangiD· 1 shared Chunyan Wang· 1 shared Dan Yang ZhaoiD· 1 shared Enming YuaniD· 1 shared Fang WaniD· 1 shared Fengcai ZhuiD· 1 shared Hainian Zeng· 1 shared

Activity by Year

2021-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperSystems Biology

Chengliang Hu

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacology & ToxicologyAntibody TherapeuticsPeer-reviewedMay 21, 2025

A Novel Bispecific Antibody CVL006 Superior to AK112 for Dual Targeting of PD-L1 and VEGF in Cancer Therapy

Chunyan Wang, Hao Huang, Zeng Song…·Xiaokun Shen

This paper develops a bispecific antibody CVL006 that targets PD-L1 and VEGF, showing superior antitumor efficacy compared to existing therapies in preclinical models.

9 citations

mouseexperimental assay

𝕏 PostBluesky

Systems BiologySignal Transduction and Targeted TherapyPeer-reviewedApr 24, 2021

A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19

Yiyue Ge, Tingzhong Tian, Suling Huang…·Jianyang Zeng

This paper presents a data-driven drug repositioning framework that identifies CVL218, a PARP1 inhibitor, as a potential therapeutic for COVID-19 through in silico and experimental validation.

300 citationstop 1%

humanmachine learning (classical)

𝕏 PostBluesky